Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with All HCV genotypes

Journal of Infectious Diseases

Volumn 205, Issue 3, 2012, Pages 376-383

  Naggie, Susanna ^a   Rallon, Norma I ^b   Benito, José M ^b   Morello, Judith ^b   Rodriguez Novoa, Sonia ^b   Clark, Paul J ^a   Thompson, Alexander J ^a   Shianna, Kevin V ^c   Vispo, Eugenia ^b   McHutchison, John G ^a   Goldstein, David B ^c   Soriano, Vincent ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CREATININE; HEMOGLOBIN; HYDROLASE; INOSINE TRIPHOSPHATASE; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INOSINE TRIPHOSPHATASE DEFICIENCY; INOSINE TRIPHOSPHATE GENE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RIBAVIRIN;

EID: 84855896797     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir754     Document Type: Article

References (32)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2005;29:74-81.
2. Graham C, Baden L, Yu E, et al. Influence of HIV infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9. (Pubitemid 32709592)
3. Weber R, Sabin C, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-41. (Pubitemid 44232373)
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD practice guidelines: diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
5. Chung RT, Anderson J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9. (Pubitemid 38988594)
6. Torriani FJ, Rodrguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50. (Pubitemid 38988593)
7. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-82. (Pubitemid 47492337)
8. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1060-9.
9. Maynard M, Gagnieu MC, Pradat P, Bailly F, Trepo C. Relevance of ribavirin plasma concentration for the prediction of treatment response. J Hepatol 2005;42(Suppl 2):224.
10. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010;464:405-8.
11. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007;8:1221-8. (Pubitemid 47578231)
12. Stocco G. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;85:164-72.
13. Sumi S. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111:360-7. (Pubitemid 36075062)
14. Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphase deficiency. J Hum Genet 2002;47:620-2. (Pubitemid 36083264)
15. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C>A and g. IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. Biochem Biophys Acta 2007;1772:96-102. (Pubitemid 44960729)
16. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a caucasian population. Clin Chem 2006;52:240-7. (Pubitemid 43185485)
17. Hitomi Y, Cirulli ET, Fellay J, et al. Inosine triphosphate protects against ribavirin-induced ATP loss by restoring adenylosuccinate synthase function. Gastroenterology 2011;140:1314-21.
18. Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011;53:415-21.
19. Medrano J, Resino S, Vispo E, et al. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV-HCV coinfected patients. J Viral Hep 2011;18:325-30.
20. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89. (Pubitemid 46763278)
21. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
22. Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-9.
23. Morello J, Rodriguez-Novoa S, Cantillano AL, et al. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis. Ther Drug Monit 2007;29:802-6. (Pubitemid 350190858)
24. Ziol M, Handra-Luca A, Kettaneh A, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54. (Pubitemid 40066382)
25. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50. (Pubitemid 40439195)
26. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-9.
27. Kirk G, Astemborski J, Mehta S, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009;48:963-72.
28. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010;139:1181-9.
29. Thompson AJ, Santon R, Piazzollo V, et al. ITPA genetic variants are protective against anemia during antiviral therapy for G 2/3 HCV, but do not decrease the need for RBV dose reduction or increase SVR. Hepatology 2010;52:785A.
30. Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010;139:1602-11.
31. Spiga MG, Weidner DA, Trentesaux C, LeBoeuf RD, Sommadossi JP. Inhibition of beta-globin gene expression by 3′-azido-3′-deoxythymidine in human erythroid progenitor cells. Antivir Res 1999;44:167-77. (Pubitemid 30017944)
32. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004. (Pubitemid 30169949)